COMMUNIQUÉS West-GlobeNewswire

BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder
29/06/2026
Nearly half of individuals diagnosed with PTSD also meet criteria for major depressive disorder (MDD), making comorbid depression one of the most common and clinically significant complications of PTSD ~83.5% of [...]
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
29/06/2026
WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer [...]
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
29/06/2026
Company expands executive team with strategic corporate affairs leader as it advances its differentiated obesity portfolio WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage [...]
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
29/06/2026
FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed modules of the NDA before the full application is submitted FDA previously granted Breakthrough Therapy [...]
Zymeworks to Acquire Theravance Biopharma, Inc.
29/06/2026
Acquisition adds YUPELRI ® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolio Acquisition of Theravance Biopharma [...]
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
29/06/2026
FDA alignment on submission of BLA data package in multi-disciplinary Type B pre-BLA meeting minutes; first module of rolling BLA submitted with remaining modules expected 2H 2026 Daily nomlabofusp increased and [...]
Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
29/06/2026
Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clinical, biomarker and safety results for Biogen’s investigational tau-targeting ASO, following topline results announced [...]
Le Dr Mariusz Sapijaszko élu président de l’Association canadienne de dermatologie
29/06/2026
OTTAWA, Ontario, 29 juin 2026 (GLOBE NEWSWIRE) -- L’Association canadienne de dermatologie (ACD) est fière d’annoncer la nomination du Dr Mariusz Sapijaszko au poste de président de l’ACD. Il assumera officiellement ses [...]
Dr. Mariusz Sapijaszko elected President of the Canadian Dermatology Association
29/06/2026
OTTAWA, Ontario, June 29, 2026 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA) is pleased to announce the appointment of Dr. Mariusz Sapijaszko as CDA President, effective June 25, 2026. Dr. Mariusz [...]
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
29/06/2026
ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant [...]
Conavi Medical Receives $1.25 Million Milestone Payment Under Ontario Life Sciences Scale-Up Fund
29/06/2026
Company has received $1.75 million in total under the program, including a $1.25 million payment triggered by the Company’s U.S. FDA clearance, to support the commercial launch of its hybrid IVUS-OCT imaging system [...]
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
29/06/2026
—Advances strategic shift toward a disciplined research model prioritizing external innovation to accelerate rare disease pipeline growth— —Completes enrollment in Phase 3 ALPHA-ORBIT for navenibart, largest pivotal HAE [...]
NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company
29/06/2026
This agreement represents NetraMark's ninth commercial contract since the start of its current fiscal year and demonstrates growing interest in AI-enabled clinical trial analytics, like NetraAI, among biopharmaceutical [...]
Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
29/06/2026
SAT-3247 has now received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations for Duchenne muscular dystrophy (“Duchenne” or “DMD”) Fast Track is designed to expedite the development/review of new drugs [...]
Dyadic Expands IP Protection and Business Development Activities in Japan
29/06/2026
Bolsters Japan Market Expansion, Strategic Collaborations and Demand for Scalable Recombinant Protein Solutions JUPITER, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the [...]
Zelluna ASA: Mandatory notification of trade – Return of lent shares following Private Placement
29/06/2026
Oslo, 29 June 2026 : Reference is made to the stock exchange announcement by Zelluna ASA (the "Company") on 18 June 2026 regarding completion of a private placement of 3,143,958 new shares at a subscription price of NOK [...]
George Medicines appoints Brendan Walsh as Senior Vice President of Supply Chain & Technical Operations
29/06/2026
Brendan Walsh brings more than 20 years of operational leadership to support George Medicines’ global commercial expansion of GMRx2 London, UK, Boston, MA, 29 June 2026 – George Medicines, a late-stage biopharmaceutical [...]
Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes
29/06/2026
SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
29/06/2026
CORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central [...]

Pages